MACULAR TELANGIECTASIA TYPE 2 (MACTEL)

Clinical trials for MACULAR TELANGIECTASIA TYPE 2 (MACTEL) explained in plain language.

Never miss a new study

Get alerted when new MACULAR TELANGIECTASIA TYPE 2 (MACTEL) trials appear

Sign up with your email to follow new studies for MACULAR TELANGIECTASIA TYPE 2 (MACTEL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

Amino acid supplement could slow vision loss in rare eye disease

Disease control Not yet recruiting

This Phase 3 study tests whether taking serine, a natural amino acid, twice daily for 24 months can slow vision loss in people with MacTel type 2, a rare eye disease that damages the retina. About 120 adults will receive either serine or a placebo. Researchers will track retinal …

Matched conditions: MACULAR TELANGIECTASIA TYPE 2 (MACTEL)

Phase: PHASE3 • Sponsor: The Lowy Medical Research Institute Limited • Aim: Disease control

Last updated May 15, 2026 06:03 UTC

MACULAR TELANGIECTASIA TYPE 2 (MACTEL)

Get alerted when new MACULAR TELANGIECTASIA TYPE 2 (MACTEL) trials appear

Amino acid supplement could slow vision loss in rare eye disease